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Abstract: Talcosis due to intravenous injection of oral drugs can cause severe pulmonary 
disease with progressive dyspnea even when drug use is discontinued. We describe a 54-year-
old woman with severe emphysema who underwent left lung transplantation. The patient had 
a remote history of intravenous injection of crushed methylphenidate (Ritalin) tablets. Chest 
computed tomography showed severe emphysematous changes, more prominent in the lower 
lobes. Microscopic examination of the extracted lung demonstrated multinucleated giant cells 
with birefringent crystals, compatible with talcosis. At follow-up, daily symptoms were com-
pletely alleviated and lung function was good. We recommend that lung transplantation be 
considered as a viable option in the treatment of talcosis.
Keywords: methylphenidate (Ritalin), emphysema
Introduction
Talc, a hydrous magnesium silicate, is used as a lubricating and diluting substance 
in many oral medications, such as methadone, methylphenidate, and pentazocine. 
Intravenous abuse of these oral medications can cause talcosis. The talc crystals are 
ﬁ  ltered by the pulmonary vascular bed, forming foreign body granulomas within the 
alveolar capillary walls and perivascular area (Gibbs et al 1992). The talc particles 
deposited in the lungs following intravenous administration are larger than those 
observed for inhaled talc, and always contain particles that exceed 10 μm (Feigin 
1986). Progressive massive ﬁ  brosis (PMF) secondary to intravenous talc injection has 
been described with particles larger than 15 μm were only found in the mass lesion 
(Crouch and Churg 1983). In contrast to intravenous administration, inhaled talc is 
usually accompanied by other minerals, such as silica or asbestos, and it is these that 
seem to have the prominent clinical, pathologic and radiographic effect in the lungs 
(Lockey 1981). In cases of talc inhalation, only small particles, usually measuring up 
to 5 μm, are ﬁ  ltered by the bronchial tree, reach the peribronchial and perivascular 
regions or forming intraalveolar talc and asbestos bodies (Katzenstein and Askin 1997). 
The early restrictive and obstructive features of talcosis due to intravenous use may 
progress to severe, sometimes fatal, pulmonary disease, even in patients who have 
discontinued use of the drug (Pare et al 1989).
Typical ﬁ  ndings on computed tomography (CT) include large and irregular 
attenuated nodules (“ground glass”) in the middle and upper part of the lung, which 
can evolve to large masses or massive consolidations (Feigin 1986). The presence of 
lower-lobe panacinar emphysematous processes is more common in methylphenidate 
abusers (Stern et al 1994; Ward et al 2000). Birefringent talc crystals can be identiﬁ  ed 
under polarized light in tissue samples.
We describe a patient with severe emphysema due to pulmonary talcosis from 
intravenous methylphenidate abuse who underwent successful lung transplantation. 
We review the literature.International Journal of COPD 2008:3(2) 328
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Case presentation
A 54-year-old woman employed as a physiotherapist 
presented to our center in August 1999 with complaints 
of dyspnea. The diagnosis was emphysema. The patient 
had a history of heavy smoking (20–40 pack-years) until 
1990 and of intravenous methylphenidate abuse for 4 years, 
20 years previously. She also had rheumatoid arthritis treated 
with prednisone 7.5 mg qd and positive serology for hepatitis 
C, presently not active, with recent undetectable plasma 
RNA levels. Lung function test showed a forced expiratory 
volume in one second (FEV1) of 28%, forced vital capacity 
(FVC) 56%, total lung capacity (TLC) 120%, residual 
volume (RV) 242%, and diffusing capacity for carbon 
monoxide (DLCO) 33% of predicted values. Treatment with 
salbutamol and ipratropium bromide inhalers was started.
Two years later, a signiﬁ  cant deterioration was noted in 
the patient's functional capacity. She was unable to conduct 
activities of daily living and became oxygen-dependent. 
Physical examination revealed diffuse bilateral crackles 
on inspiration, predominantly in the lower lobes, without 
wheezing. Chemistry proﬁ  le and blood count were within 
normal limits. Room air arterial blood gas demonstrated pH 
7.43, partial pressure of carbon dioxide (PCO2) 43 mmHg, 
and partial pressure of oxygen (PO2) 65 mmHg. Resting 
oxygen saturation was 92% and decreased to 87% after a 
1-minute walk. Chest X-ray ﬁ  lm (Figure 1) demonstrated 
bullous emphysema and ﬁ  brotic changes, predominantly in 
the lower lobes. High-resolution CT of the chest (Figure 2) 
was consistent with emphysema, with marked hyperinﬂ  ation 
of both lower lobes. In addition, bibasilar scarring involving 
mainly the right middle lobe and lingular segments was noted. 
There was no evidence of interstitial ﬁ  brosis.
Quantitative perfusion lung scan showed reduced perfu-
sion to the lower lung zones with virtual lack of perfusion 
to the left lower lobe and to the lower third of the right lung. 
In the upper lung zones, the perfusion was mildly heteroge-
neous. Overall perfusion to the left lung was 41%. Blood 
levels of C-reactive protein, alpha-1 antitrypsin, rheumatoid 
factor, antinuclear antibodies, antineutrophil cytoplasmic 
autoantibody and complement were within normal limits. 
Blood test for human immunodeﬁ  ciency virus was negative. 
Findings on echocardiography were normal except for mild 
pulmonary hypertension, and heart catheterization demon-
strated normal coronary arteries, pulmonary artery pressure 
of 40/13 mmHg (mean 29), and pulmonary wedge capillary 
pressure of 12 mmHg.
The patient was referred for lung transplantation, which 
was performed on December 15, 2003. In order to double 
our transplant recipients, we prefer conducting single lung 
transplantation in cases not involving chronic lung infections 
such as cystic ﬁ  brosis or bronchiectasis. We chose to conduct 
left lung transplantation in this patient according to the less 
perfused left lung (41%). The transplantation procedure as 
well as the postoperative course were unremarkable, with no 
signiﬁ  cant complications other than Nocardia pneumonia in 
the native lung, which resolved after a prolonged antibiotic 
course. A few months after transplantation, the patient 
resumed her normal activities. Oxygen saturation was 
normal on follow-up, with FEV1 ranging between 54% and 
43% of predicted values. At the last visit, 3.5 years after 
transplantation, the patient was active and FEV1 was 49% 
of predicted on lung function test.
Pathologic examination of the extracted lung revealed 
macroscopic evidence of hyperinﬂ  ation, with two lymph 
nodes showing hilar anthracosis. On microscopic exami-
nation (Figure 3), lymphocytic foci, congestion, and 
Figure 1 Chest X-ray ﬁ  lm.  A. Before transplantation, showing bilateral hyperinﬂ  ation. 
Note also the increased interstitial marking and scarring in the basilar portions.  B.   Two 
months after left lung transplantation, showing well-inﬂ  ated left lung.
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The patient described here had progressive dyspnea 
despite discontinuation of drug abuse. Her lung functions 
were compatible with severe emphysema, and chest CT 
revealed an emphysematous pattern in the base of the lung 
but without nodules or masses and no evidence of interstitial 
ﬁ  brosis. Although the patient had a past history of cigarette 
smoking, we would have expected emphysema in the upper 
lung zones had cigarettes been the cause. Alpha-1 antitrypsin 
deﬁ  ciency, which can also cause lower-lobe emphysema, was 
ruled out by normal blood levels. In our patient, the lower 
lobe emphysema seemed to be compatible with her history 
of talc injection.
Our review of the literature yielded 2 cases of lung 
transplantation in patients with pulmonary talcosis sec-
ondary to intravenous drug abuse. In the case described 
by Cook and colleagues (1998), the pulmonary talcosis 
recurred 18 months following single-lung transplantation. 
After the transbronchial biopsy showed evidence of talcosis 
in the transplanted lung, the patient, a 48-year-old former 
Figure 2 CT scan of the chest demonstrating severe emphysematous changes with 
bullous formation and scarring.
Figure 3 Pathologic study of the extracted lung.   A. Note focal interstitial 
lymphocytic inﬁ  ltrates (lower-left ﬁ  eld) and giant foreign cells (arrows) with evi-
dence of foreign material in the cytoplasm (hematoxylin-eosin; magniﬁ  cation × 200). 
B. Polarized particles in the interstitium and cytoplasm of the giant cells can be seen 
(magniﬁ  cation × 100).
A
B
multinuclear giant foreign body cells with a foreign substance 
in their cytoplasm were seen. The foreign substance, which 
was birefringent under polarized light, measured at least 
5–10 μm, compatible with intravenously injected talc.
Discussion
Intravenous abuse of crushed oral medication can cause 
severe pulmonary disease. Pare and colleagues (1979, 1989) 
conducted a long-term follow-up of talcosis due to drug abuse 
of oral medication in 6 patients aged 23 to 51 years. All had 
severe progressive dyspnea despite their discontinuation of 
the drug. Chest radiographs revealed a gradual coalescence 
of nodules that eventually resulted in large, more or less 
homogeneous opacities in the perihilar and upper lobe regions. 
With time, hypertranslucency, oligemia, and bullae, mostly in 
the lower lung regions, became prominent. Pneumothoraces 
developed in 3 patients. Early pulmonary function tests 
demonstrated a combined restrictive and obstructive pattern, 
with no evidence of hyperinﬂ  ation in most of the patients. 
However, long-term follow-up revealed rapidly progressive 
emphysematous features, namely, severe airﬂ  ow obstruction, 
air trapping, and reduced diffusing capacity. Pathologic 
examination showed lung destruction, granuloma formation, 
and marked ﬁ  brosis. In a similar study, Sieniewicz and 
Nidecker (1980) described 4 patients with conglomerate 
pulmonary disease associated with intravenous injection 
of crushed methadone tablets. Chest X-ray ﬁ  lm showed a 
micronodular pattern in 3 cases which later blended into 
masses in the upper lobes. The remaining patient had 
mediastinal adenopathy followed by the development of 
bilateral pneumothoraces.International Journal of COPD 2008:3(2) 330
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intravenous methylphenidate abuser, admitted to recurrent 
intravenous drug abuse. The second patient was one of a 
series of intravenous oral drug abusers described by Stern 
and colleagues (1994). The patient underwent single-lung 
transplantation for basilar emphysema caused by intravenous 
injection of crushed methylphenidate tablets. The extracted 
lung was examined pathologically, but the authors provided 
no clinical data on this case. Recently, Fields and colleagues 
(2005) described a 24-year-old woman after bilateral lung 
transplantation for cystic ﬁ  brosis in whom microcrystalline 
cellulose embolization was detected on routine transbronchial 
biopsy. The patient admitted injecting crushed promethazine 
tablets through her intravenous port in order to control severe 
nausea caused by cytomegaloviral gastritis. She had no his-
tory of intravenous drug abuse, and histological examination 
of her native lungs was negative for intravascular or paren-
chymal foreign material.
Organ transplantation in substance abusers is contro-
versial because of the possibility of relapse, even in those 
after long-term abstinence. Most of the information on this 
issue derives from studies of patients with alcoholism, also 
associated with a high relapse rate. The emerging data favor 
performing liver transplantation in selected patients after 
careful psychological evaluation since only few patients will 
resume heavy drinking after the transplantation (DiMartini 
et al 2002). In patients with drug-induced talcosis, clinicians 
should bear in mind that the dose-injury relationship has not 
yet been established.
Our patient was referred for single-lung transplantation 
because of severe emphysema mainly in the lower lobes. Her 
symptoms were completely alleviated by the procedure. Her 
intravenous use of crushed methylphenidate tablets in the 
past together with the normal blood alpha-1 antitrypsin levels 
indicated a diagnosis of lower-lobe emphysema secondary 
to talcosis. Pathologic examination of the extracted lung 
revealed the characteristic evidence of talcosis consequent 
to intravenous injection of talc.
We conclude that the mid-term outcome of lung 
transplantation in patient with talcosis is similar to that for 
other diagnoses. We recommend that lung transplantation 
be considered as a viable option in the treatment of talco-
sis. However, candidates should undergo a comprehensive 
psychiatric assessment to minimize the risk of recurrence of 
substance abuse after treatment.
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